Financial Results Schedules, Discontinuation of Phase 3 Trial, Data Presentations, Strategic Alliances, and Premarket Filings - Research Report on Biogen, Ariad, BioMarin, Alnylam, and Sequenom Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, October 23, 2013 NEW YORK, October 23, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Sequenom Inc. (NASDAQ: SQNM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Biogen Idec Inc. Research Report On October 7, 2013, Biogen Idec Inc. (Biogen) announced that it will release its Q3 2013 financial results on Monday, October 28, 2013 before the opening of financial market. The Company informed that it will also conduct a live webcast of a conference call on the same day at 9:00 a.m. ET to discuss the financial results. Biogen stated that the live webcast and an archived version of the call will be available at the investor relations section of its website for one month. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b95b_BIIB] -- Ariad Pharmaceuticals Inc. Research Report On October 18, 2013, Ariad Pharmaceuticals, Inc. (Ariad) announced the discontinuation of its Phase 3 Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia (EPIC) trial of Iclusig (Ponatinib) in patients with newly diagnosed chronic myeloid leukemia. According to the Company, the EPIC trial was a randomized, two-arm, multicenter trial that sought to compare the efficacy of ponatinib with that of imatinib in adult patients with newly diagnosed CML in the chronic phase. According to Ariad, the Company and the U.S. Food and Drug Administration have mutually agreed to terminate the trial due to arterial thrombotic events that were observed in patients treated with Iclusig. The Company added that the trial termination decision was made in the interest of patient safety based on a recent assessment of data in the clinical trial. The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/161c_ARIA] -- BioMarin Pharmaceutical Inc. Research Report On October 20, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that the Company is presenting five data presentations on its BMN 673 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, being held from October 19 to October 23, 2013. BioMarin informed that the research as reported on the poster concluded that BMN 673 was approximately 100-fold more potent than olaparib and rucaparib at trapping PARP, making it the most potent clinical PARP inhibitor to date with the highest efficiency at trapping PARP-DNA complexes. "We believe PARP trapping seen with BMN 673 is differentiating because BMN 673 appears to be significantly more lethal to cancer cells than olaparib and rucaparib, and PARP trapping may explain why BMN 673 shows far greater potency," said Hank Fuchs, M.D., Chief Medical Officer at BioMarin. "We're looking forward to further studies in gBRCA metastatic breast cancer patients to confirm and extend the early clinical results of the compound." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6c_BMRN] -- Alnylam Pharmaceuticals, Inc. Research Report On October 9, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that its strategic alliance with The Medicines Company has produced a lead Development Candidate that is a subcutaneously administered RNAi therapeutic (ALN-PCSsc) targeting PCSK9 for the potential treatment of hypercholesterolemia. John Maraganore, PhD, CEO of Alnylam said, "We have rapidly advanced the ALN-PCS collaboration to reach our first goal, which was to designate our Development Candidate by the end of this year. We anticipate submitting an investigative new drug application for ALN-PCSsc with the US Food and Drug Administration in late 2014. This is an important program within our 'Alnylam 5x15' product development and commercialization strategy focused on RNAi therapeutics directed toward genetically validated targets." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY] -- Sequenom Inc. Research Report On October 2, 2013, Sequenom, Inc. (Sequenom) announced its filing of Premarket 510(k) Notifications to the United States Food and Drug Administration (FDA) for its IMPACT Dx™ System and its IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test. According to the Company, the system and test are intended for use in the clinical laboratory setting. The Company also informed that in anticipation of applying the CE mark for the IMPACT Dx System, Sequenom has also received ISO 13485:2003 and EN ISO 13485:2012 certification for its quality management system. The Company added that it is finalizing plans to commercialize the IMPACT Dx System in a number of European countries that require CE marking. Michael Monko, Senior Vice President, Genetic Analysis at Sequenom said, "The submission of our premarket notifications is a tremendous achievement that we believe contributes significant value to our Genetic Analysis business segment and represents the transition of our proven research-use-only MassARRAY® System into the clinical diagnostics arena." The Full Research Report on Sequenom Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d291_SQNM] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Financial Results Schedules, Discontinuation of Phase 3 Trial, Data Presentations, Strategic Alliances, and Premarket Filings -
Press spacebar to pause and continue. Press esc to stop.